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Background:  We  sought  to  evaluate  the potential  utility  of echocardiography-derived  morphological  and
functional  right  ventricular  (RV)  variables  for  assessing  disease  severity  of  pulmonary  arterial  hyperten-
sion  (PAH)  and  determining  the  changes  in the  patient’s  hemodynamics  in  the  clinical  course.
Methods  and results:  This  study  consisted  of  24  normal  controls  (the  control  group)  and  24 patients  with
PAH at rest  or with  exercise  (the  PAH  group)  who  underwent  echocardiography,  right  heart  catheter-
ization,  plasma  brain  natriuretic  peptide  (BNP)  measurement,  and  six-minute  walk  distance  (6MWD)
test.  The  PAH group  had  poorer  RV  echocardiographic  variables  than  the  control  group.  RV  Tei-index
was  more  strongly  correlated  with  6MWD,  BNP,  cardiac  index,  mean  pulmonary  arterial  pressure,  and
pulmonary  vascular  resistance  (PVR)  than  other  RV echocardiography-derived  variables  including  RV
end-diastolic  areas,  RV fractional  area  change,  and tricuspid  annular  plane  systolic  excursion.  In  16  of
the 24  patients  who  successfully  underwent  repeated  examination  during  follow  up  (13.3  ± 4.9  months;
range,  5–24  months),  PVR  decreased  from  486  ±  380  dyne  s  cm−5 to  346  ± 252  dyne  s cm−5, and  RV  Tei-
index decreased  from  0.55  ± 0.30  to 0.42  ±  0.17,  and  the  changes  in  RV  Tei-index  were  correlated  with
the  concomitant  changes  in  PVR  during  the  clinical  course  of PAH  (r = 0.706,  p = 0.002).  Tricuspid  annular
plane  systolic  excursion  and  RV  fractional  area  change  did  not  change  during  the  follow  up.
Conclusions:  Quantitative  echocardiography  revealed  that  the  measurement  of RV  Tei-index  is of  great
clinical  utility  for predicting  disease  severity  of  PAH  and determining  the  changes  in the  patient’s  hemo-
dynamics  in  the  clinical  course.
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Pulmonary arterial hypertension (PAH) is a rare but life-
hreatening disease. PAH comprises apparently heterogeneous
isease conditions that share comparable clinical and hemody-
amic conditions and virtually identical pathological changes of
he lung microcirculation, including luminal narrowing of muscu-
ar pulmonary arteries and plexiform lesions. Without adequate
herapy, such pulmonary vascular remodeling will progress and
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eventually lead to right ventricular (RV) failure and death [1].
However, the treatment of PAH has advanced and dramatically
improved the outcome in recent years.
Echocardiography is a noninvasive and useful tool for diag-
nosing PAH, assessing disease severity, and determining response
to treatment [2,3], and echocardiography-derived morphological
and functional RV variables including RV areas and fractional area
change (FAC), tricuspid annular plane systolic excursion (TAPSE),
and RV Tei-index may  have potential for predicting the disease
severity of PAH and determining response to treatment. However,
there are few reported studies that evaluated which echocardio-
graphic variable is the best marker in response to treatment of
PAH. Accordingly, we aimed to identify the best echocardiography-
derived variable for predicting the disease severity of PAH and
determining the changes in the patient’s conditions by comparison
vier Ltd. All rights reserved.
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ith the symptoms, exercise tolerance, plasma brain natriuretic
eptide (BNP), and hemodynamic parameters in the clinical course
f PAH with or without vasodilator therapy.
atients and methods
tudy population
We  enrolled 26 consecutive patients with evidence of either
AH at rest (n = 15) or with exercise (n = 11) conﬁrmed by right
eart catheterization (RHC) between January 2010 and December
011. PAH was  deﬁned as mean pulmonary artery pressure
PAP) ≥25 mmHg  and pulmonary capillary wedge pressure (PCWP)
15 mmHg  at rest [4]. Exercise-induced PAH was deﬁned as mean
AP ≥30 mmHg  and PCWP ≤20 mmHg  with exercise [5]. One
atient was excluded because of old myocardial infarction and an
mplanted permanent pacemaker, and one patient was excluded
ecause of intracardiac shunt. Our study population did not include
trial ﬁbrillation. Accordingly, the study group consisted of 24
atients (the PAH group; mean age 52 ± 16 years, range 21–78
ears, 2 men). We  also studied 24 age-matched normal subjects
control group; mean age 54 ± 15 years, range 19–82 years, 6 men)
ho had no history of cardiopulmonary disease, normal electro-
ardiographic results, and normal echocardiographic results. The
tudy was approved by the local ethical review board of our insti-
ution. Written informed consent was obtained from all patients.
chocardiography
All subjects underwent complete transthoracic echocardiogra-
hy using a Vivid 7 system (GE-Vingmed Ultrasound AS, Horten,
orway) within 2 days before or after the RHC [6,7]. LV ejec-
ion fraction was assessed by biplane Simpson’s rule. The ratio
f peak early to late diastolic transmitral ﬂow velocity (mitral
/A) was calculated by pulsed Doppler echocardiography [8]. Peak
arly diastolic mitral annular velocity (Ea) on the inferior-septum
as measured from the apical four-chamber view. The E/Ea ratio
as calculated as a Doppler parameter reﬂecting LV ﬁlling pres-
ure [9]. LV eccentricity index, deﬁned as the ratio of the LV
nterior-to-posterior dimension to the septal-to-lateral dimension
t end-diastole from the mid-ventricular short-axis image, was
sed as an index of septal geometric abnormality caused by RV
iastolic pressure overload [7,10]. RV end-diastolic area (RVEDA)
nd RVFAC were also measured from the apical four-chamber view
2]. TAPSE was measured as the total displacement of the lateral
ortion of the tricuspid annular plane by M-mode tracing [11]. RV
jection time (RVET) was measured as the interval from the onset
o the end of the RV outﬂow proﬁle. The sum of isovolumetric
ontraction time (ICT) and isovolumetric relaxation time (IRT) was
easured as the interval from the cessation to the onset of the tri-
uspid inﬂow. RV Tei-index was measured as the sum of ICT and IRT
ivided by the RVET as described previously [12]. All echocardio-
raphic measurements represent the average of 3 beats and were
nalyzed later ofﬂine by experienced observers who were unaware
f each patient’s clinical proﬁle. Intra- and interobserver variability
ere analyzed in 10 randomly selected subjects from the control
roup or PAH group and expressed as the mean percentage error
difference/mean).
ix-minute walk distance testAll patients in the PAH groups underwent a six-minute walk dis-
ance (6MWD) test within 2 days before or after the RHC, except for
 patients because of resting dyspnea or joint pain. The 6MWD  test
as performed by a trained cardiologist on a 30-m corridor withiology 63 (2014) 149–153
no prior practice walks in accordance with the American Thoracic
Society guidelines [13].
Right heart catheterization
All patients in the PAH group underwent an RHC via the right
internal jugular vein in the non-fasting state before the patients’
usual morning medications. PAP, PCWP, and right atrial pres-
sure (RAP) were measured using standard ﬂuid-ﬁlled catheters.
Estimated cardiac output (CO) was  measured by the thermodilu-
tion method [14]. None of the patients received oxygen therapy
during RHC. Arm-cuff blood pressure measurements and BNP
measurements were performed simultaneously with RHC. The
following formulas were used to calculate standard hemody-
namic parameters derived from the above measurements: Cardiac
index (CI) = CO/body surface area; pulmonary vascular resistance
(PVR) = (mean PAP − mean PCWP) × 80/CO.
Follow-up examination
All patients received clinical care during the study periods in
accordance with existing guidelines and reviews [4,15]. To peri-
odically evaluate whether the disease progressed or to determine
the effect of PAH-speciﬁc drugs, repeated examinations including
transthoracic echocardiography, exercise capacity test, and RHC
were successfully performed in 16 patients with a mean follow-up
period of 13.3 ± 4.9 months (range, 5–24 months).
Statistical analysis
All statistical analyses were performed with SPSS, version
11.5 (SPSS Inc., Chicago, IL, USA). Data are expressed as mean
value ± standard deviation. The signiﬁcance of differences between
groups was  evaluated by two-sample t test and Mann–Whitney’s
U test. The signiﬁcance of differences between the initial and
follow-up variables was  evaluated by paired t test and Wilcoxon’s
signed-rank test. The correlation between echocardiographic vari-
ables and hemodynamic parameters, 6MWD,  or BNP was calculated
using Spearman’s rank correlation coefﬁcient, which is denoted by
rs. Because BNP values were not normally distributed, log BNP was
used in the statistical analysis [16]. A p-value of < 0.05 was  consid-
ered statistically signiﬁcant.
Results
Baseline characteristics
The clinical characteristics of the study subjects are shown
in Table 1. All 11 patients with exercise-induced PAH had con-
nective tissue disease (CTD). There were no statistical differences
in physical constitution, systemic blood pressure, and heart rate
between the PAH group and the control group. The majority of
the PAH group (75%) had a World Health Organization functional
class (WHO-FC) of I or II. The 6MWD  and the BNP level in the
PAH groups were 473 ± 80 m and 79 ± 133 pg/ml, respectively.
The results of baseline invasive pulmonary hemodynamic mea-
surements in the PAH groups were as follows: RAP 6 ± 3 mmHg,
mean PAP 35 ± 21 mmHg, PVR 510 ± 485 dyne s cm−5, and CI
3.3 ± 0.8 L min−1 m−2. Ten patients were receiving PAH-speciﬁc
drugs including phosphodiesterase type-5 inhibitors, endothelin
receptor antagonists, and/or prostanoids, but no patients were
receiving long-term oxygen. Four patients were receiving diuretics.
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Table  1
Clinical and hemodynamic characteristics of the control group and the PAH group
at  enrollment.
Characteristics Control (n = 24) PAH (n = 24)
Age, years 54 ± 15 52 ± 16
Female gender, no. (%) 18 (75) 22 (92)
Cause of PAH, no.
Idiopathic − 6
Portal hypertension − 2
Connective tissue disease − 16
Height, cm 157 ± 11 157 ± 8
Weight, kg 54 ± 12 52 ± 13
Body mass index, kg/m2 22 ± 3 21 ± 4
Systolic blood pressure, mmHg  115 ± 13 122 ± 24
Diastolic blood pressure, mmHg  69 ± 10 70 ± 9
Heart rate, beats/min 65 ± 11 72 ± 13
Medication, no.
Sildenaﬁl − 2
Sildenaﬁl + bosentan − 1
Sildenaﬁl + beraprost − 2
Sildenaﬁl + epoprostenol − 2
Sildenaﬁl + bosentan + beraprost − 1
Sildenaﬁl + bosentan + treprostinil − 2
Diuretics − 4
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Table 3
Spearman’s Rank correlation coefﬁcients relating enrollment clinical and hemody-
namic variables of PAH to echocardiographic variables of RV function.
6MWD  log BNP CI Mean PAP PVR
RVEDA −0.172 0.448* −0.297 0.782* 0.734*
RVFAC 0.160 −0.474* 0.365 −0.801* −0.768*
TAPSE 0.333 −0.180 0.348 −0.539* −0.531*
RV Tei-index −0.587* 0.507* −0.438* 0.794* 0.798*
Data are presented as rs value. Three patients could not perform 6-min walk test
because of dyspnea or joint pain.
PAH, pulmonary arterial hypertension; RV, right ventricular; 6MWD,  six-minute
walk distance; BNP, plasma brain natriuretic peptide; CI, cardiac index; PAP,
pulmonary artery pressure; PVR, pulmonary vascular resistance; RVEDA, right ven-ata are presented as no. or mean ± SD.
AH, pulmonary arterial hypertension.
lectrocardiographic and echocardiographic variables at
nrollment
The PAH group had prolonged QRS duration compared with the
ontrol group (Table 2). There was no signiﬁcant difference in LV
jection fraction and eccentricity index between the groups. In con-
rast, the PAH group had a signiﬁcantly larger RV area, lower systolic
V function including TAPSE and RVFAC, and higher RV Tei-index
han the control group.
elationship between echocardiography-derived RV variables and
linical and hemodynamic variables of PAH at enrollment
The associations of echocardiography-derived RV variables with
linical and hemodynamic variables of PAH at enrollment are illus-
rated in Table 3. Only RV Tei-index was signiﬁcantly correlated
ith all clinical and hemodynamic variables, especially with PVR
Fig. 1A).
able 2
lectrocardiographic and echocardiographic variables of the control group and the
AH group at enrollment.
Characteristics Control (n = 24) PAH (n = 24)
QRS duration, ms 85 ± 8 95 ± 16*
LV ejection fraction, % 65 ± 6 66 ± 8
Mitral E/A 1.0 ± 0.4 1.0 + 0.5
Mitral Ea, cm/s 7.1 ± 2.0 5.9 ± 2.4
Mitral E/Ea 10 ± 3 11 ± 4
LV  eccentricity index 1.01 ± 0.08 1.20 ± 0.34
RVEDA, cm2 13 ± 3 20 ± 8*
RVFAC, % 52 ± 6 42 ± 11*
TAPSE, mm 23 ± 3 19 ± 5*
RV Tei-index 0.26 ± 0.12 0.54 ± 0.34*
ata are presented as mean ± SD.
AH, pulmonary arterial hypertension; LV, left ventricular; Mitral E/A, ratio of peak
arly to late diastolic transmitral ﬂow velocity; Mitral Ea, peak early diastolic mitral
nnular velocity; Mitral E/Ea, ratio of peak early diastolic transmitral ﬂow velocity to
eak early diastolic mitral annular velocity; RVEDA, right ventricular end-diastolic
rea; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane
ystolic excursion; RV, right ventricular.
* p < 0.05.tricular end-diastolic area; RVFAC, right ventricular fractional area change; TAPSE,
tricuspid annular plane systolic excursion.
* p < 0.05.
RV Tei-index and clinical and hemodynamic variables in the
course of PAH
Comparisons of clinical, echocardiographic, and hemodynamic
variables between baseline and follow-up in 16 patients who
underwent follow-up examination are illustrated in Table 4. Of
the 16 patients, 8 patients had already been receiving PAH-speciﬁc
drugs. During the follow-up of the 8 patients, 1 patient discontinued
using the drug because of a side effect, and another switched the
drugs, and 3 patients received additional drugs. Six patients newly
started receiving PAH-speciﬁc drugs. Neither heart rate nor QRS
duration signiﬁcantly changed. At follow-up, 6MWD  signiﬁcantly
increased and mean PAP and PVR signiﬁcantly decreased. RVFAC
and TAPSE did not change during the course. However, RVEDA and
RV Tei-index signiﬁcantly decreased.
We evaluated whether RV Tei-index, which signiﬁcantly
improved during the time course of PAH, was  associated with
changes in clinical and hemodynamic parameters. Although
changes in RV Tei-index did not correlate with changes in 6MWD,
log BNP, or CI, they strongly correlated with the changes in mean
PAP (rs = 0.688, p < 0.005; data not shown) and the changes in PVR
(Fig. 1B) during the course. Although only 2 of 16 patients exhib-
ited improvement in WHO  FC at the follow-up, both RV Tei-index
and PVR dramatically decreased in these patients (Fig. 1B, red cir-
cles). One 21-year-old woman  with idiopathic PAH was treated
with the combination of sildenaﬁl 60 mg  and epoprostenol to a
maximum dose of 10 ng/kg/min after RHC at enrollment. After 7
months, she improved from WHO  FC III to II with improvement in
her PVR from 928 dyne s cm−5 to 671 dyne s cm−5 and in her RV Tei-
index from 1.02 to 0.61. The second patient, a 36-year-old woman
with idiopathic PAH was  treated with the combination of sildenaﬁl
60 mg  and ambrisentan 5 mg.  After 1 year, she improved from WHO
FC IV to II with improvement in her PVR from 972 dyne s cm−5 to
396 dyne s cm−5 and in her RV Tei-index from 1.1 to 0.4.
Inter-observer and intra-observer variabilities were 5.5 ± 4.8%
and 4.8 ± 2.5% for RV Tei-index, respectively.
Discussion
The major ﬁndings of our study include the following: (1) RV
Tei-index was  strongly associated with clinical and pulmonary
hemodynamic variables; and (2) improvement in RV Tei-index but
not RVFAC and TAPSE correlated with improvements of PVR during
the clinical course in patients with PAH.
There is a growing literature on studies that evaluated the
utility of RV Tei-index in the assessment of RV function and in
the prediction of an adverse outcome in patients with pulmonary
hypertension [17,18]. RV Tei-index is independent of heart rate and
ventricular geometry [17,19], but its independence of ventricular
loading conditions remains unclear. Tei et al. demonstrated that RV
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eferences to color in this ﬁgure legend, the reader is referred to the web version of
ei-index was not correlated with RV systolic pressure and diastolic
AP in 26 patients with idiopathic PAH and RV dysfunction [12].
dditionally, Eidem et al. demonstrated that RV Tei-index did not
hange after intervention to relieve the volume or the pressure in
3 patients with atrial septal defects or isolated pulmonary valve
tenosis who had normal RV function [18]. However, some reports
howed that RV Tei-index could increase in response to increased
oading conditions in animal models and patients with pulmonary
ypertension [20–24]. Dyer et al. demonstrated that not only RV
ei-index was correlated with mean PAP (r = 0.94, p < 0.01) but also
hat the changes in RV Tei-index were correlated with changes in
ean PAP after the administration of bosentan in 12 children with
PAH [23]. Additionally, Blanchard et al. demonstrated that RV Tei-
ndex was well correlated with PVR before and after pulmonary
hromboendarterectomy in 93 patients with chronic thromboem-
olic pulmonary hypertension [24]. In our study, RV Tei-index was
orrelated with mean PAP and PVR at enrollment, and the changes
n RV Tei-index were correlated with the changes in mean PAP
nd PVR during the clinical course of PAH by medical treatment.
able 4
lectrocardiographic, echocardiographic, clinical and hemodynamic variables of
AH  at enrollment and follow-up.
Variable Enrollment (n = 16) Follow-up (n = 16)
HR, beats/min 70 ± 11 72 ± 13
QRS duration, ms  96 ± 16 98 ± 16
6MWD,  m 486 ± 53 540 ± 80*
BNP, pg/dL 86 ± 156 36 ± 42
CI,  L min−1 m−2 3.3 ± 0.8 3.3 ± 0.7
Mean PAP, mmHg  36 ± 18 29 ± 16*
PVR, dyne s cm−5 486 ± 380 346 ± 252*
RVEDA, cm2 22 ± 9 18 ± 7*
RVFAC, % 39 ± 11 41 ± 13
TAPSE, mm 19 ± 4 20 ± 4
RV  Tei-index 0.55 ± 0.30 0.42 ± 0.17*
ata are presented as no. or mean ± SD. Two patients could not perform 6-min walk
est because of dyspnea or joint pain at enrollment. One patient could not perform
-min walk test because of joint pain at follow up.
R, heart rate; PAH, pulmonary arterial hypertension; RV, right ventricular; 6MWD,
ix-minute walk distance; BNP, plasma brain natriuretic peptide; CI, cardiac index;
AP,  pulmonary artery pressure; PVR, pulmonary vascular resistance; RVEDA, right
entricular end-diastolic area; RVFAC, right ventricular fractional area change;
APSE, tricuspid annular plane systolic excursion.
* p < 0.05. = 0.002). Red circles indicate the patients whose WHO-FC improved (B). RV,  right
; WHO-FC, World Health Organization functional class. (For interpretation of the
rticle.)
In light of these ﬁndings, it is possible that RV Tei-index is in part
afterload-dependent.
Forﬁa et al. reported that TAPSE strongly reﬂects RV function
and prognosis in PAH, and that TAPSE correlated inversely with
PVR [11]. Brown et al. demonstrated that the RV dysfunction seen
in PAH is characterized by more prominent impairment of longi-
tudinal than of transverse motion, and that serial monitoring of
TAPSE as a longitudinal measure of RV function may  play an impor-
tant role in monitoring whether RV afterload decreases in response
to the therapy [25]. Our ﬁndings also showed that TAPSE corre-
lated inversely with PVR and mean PAP at enrollment, but that RV
Tei-index as well as PVR signiﬁcantly improved after the therapy
in the situation in which systolic RV function variables including
TAPSE did not signiﬁcantly change, suggesting that RV Tei-index
is more useful in assessing response to medical treatment. That
may  be because RV Tei-index does not only represent systolic RV
function but also RV global function. However, in Forﬁa’s patient
population, unlike our study, the majority of the PAH group (70%)
had a WHO-FC of III or IV. This means that more patients had poor
RV dysfunction and pulmonary hemodynamics. If our study had
included more patients with severe PAH, this marker might have
been correlated with pulmonary hemodynamics.
Some studies reported that RV Tei-index has relationships with
exercise capacity and symptoms [12,26]. Our results also show
that RV Tei-index correlated with 6MWD  at enrollment in our 22
patients, and that RV Tei-index markedly improved in the patients
whose WHO  FC improved. These ﬁndings suggest that there is some
sort of relationship between RV Tei-index and symptoms. How-
ever, RV Tei-index did not signiﬁcantly correlate with 6MWD  at
follow up. A possible cause of this discrepancy is that the number of
cases in our study was  small, and the majority of patients had pre-
served exercise capacity (6MWD  >450 m,  71% of the PAH group).
Degano et al. have reported that 6MWD  was less sensitive than
hemodynamic variables and symptoms in detecting changes sec-
ondary to PAH-speciﬁc therapy in a cohort study of 49 patients with
6MWD  > 450 m,  which may  point to a ceiling effect [27]. Further
studies on patients with poor exercise capacity and symptoms will
be required to deﬁne whether changes in RV Tei-index are related
to changes in exercise capacity and symptoms.
The current study included heterogeneous causes of PAH, with a
variety of treatments and follow-up periods. In addition, because of
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Simonneau G. Characterization of pulmonary arterial hypertension patientsY. Ogihara et al. / Journal o
he small sample population, we could not perform subgroup anal-
sis and assess the treatment itself. Furthermore, the PAH group
ncluded some patients with exercise-induced PAH. The patients
ith exercise-induced PAH have early microcirculation loss which
s not accompanied by a change in resting PAP. Therefore, exercise-
nduced PAH may  have been thought as early stage of pulmonary
ascular disease in PAH [28], and we added them into our patient
opulation. Our patients with exercise-induced PAH had almost
ormal exercise capacity, mild symptoms, mild pulmonary hemo-
ynamic abnormalities, and mildly impaired or normal RV systolic
unction. Even the patient group without exercise-induced PAH had
ood correlations between RV Tei-index and PVR or between RV
ei-index and mean PAP (rs = 0.560, p < 0.05 or rs = 0.576, p < 0.05,
espectively). Although we statistically showed the utility of RV
ei-index for assessing PAH, future studies with a larger number
f patients with severe hypertension, such as elevated RAP and
arked impairment of RV systolic function, will be required to
onﬁrm our ﬁndings.
onclusions
In PAH patients, RV Tei-index was strongly correlated with clin-
cal and pulmonary hemodynamic variables, especially PVR, and
he improvement in RV Tei-index was correlated with the improve-
ent in afterload by PAH-speciﬁc therapy. These ﬁndings suggest
hat the measurement of RV Tei-index is of great clinical utility for
redicting the disease severity of PAH and determining the changes
n the patient’s hemodynamics.
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